Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Two firms will collaborate on the development and marketing of new psychiatric products, including an intramuscular depot formulation of the blockbuster antipsychotic medicineLundbeck Inc. , Abilify.

Advertisement

Related Content

Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Otsuka And Lundbeck Begin To Reap Rewards Of Partnership
Drug Approval News, In Brief
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2011
Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel